Contact
searchSearch
HMP Global
Login
News
177Lu-Edotreotide Extends Progression-Free Survival vs Everolimus in GEP-NETs
10/28/2025
Janelle Bradley
¹⁷⁷Lu-edotreotide significantly improved progression-free survival and objective response rates compared to everolimus in patients with advanced GEP-NETs, with consistent benefits across tumor grades, sites, and prior treatment settings,...
¹⁷⁷Lu-edotreotide significantly improved progression-free survival and objective response rates compared to everolimus in patients with advanced GEP-NETs, with consistent benefits across tumor grades, sites, and prior treatment settings,...
¹⁷⁷Lu-edotreotide significantly...
10/28/2025
Radiopharmaceutical Education Institute
News
Obrixtamig Demonstrates Promising Efficacy in DLL3-High Extrapulmonary Neuroendocrine Carcinoma
10/28/2025
Janelle Bradley
Obrixtamig, a DLL3/CD3 bispecific T-cell engager, demonstrated a 40% objective response rate and durable, manageable activity in patients with DLL3-high extrapulmonary neuroendocrine carcinoma, according to a phase 1 trial.
Obrixtamig, a DLL3/CD3 bispecific T-cell engager, demonstrated a 40% objective response rate and durable, manageable activity in patients with DLL3-high extrapulmonary neuroendocrine carcinoma, according to a phase 1 trial.
Obrixtamig, a DLL3/CD3...
10/28/2025
Oncology
News
TAE and cTACE Show Comparable Efficacy for Liver-Dominant Neuroendocrine Tumor Metastases
10/28/2025
Janelle Bradley
Findings from an international randomized trial show transarterial embolization (TAE) and conventional chemoembolization (cTACE) demonstrated comparable efficacy for liver-dominant neuroendocrine tumor metastases, though TAE was associated...
Findings from an international randomized trial show transarterial embolization (TAE) and conventional chemoembolization (cTACE) demonstrated comparable efficacy for liver-dominant neuroendocrine tumor metastases, though TAE was associated...
Findings from an international...
10/28/2025
Oncology
News
212Pb-DOTAMTATE Demonstrates Promising Activity After Prior PRRT in Advanced GEP-NETs
10/28/2025
Janelle Bradley
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE achieved a 30.8% objective response rate and a 96% disease control rate with a manageable safety profile in patients with advanced SSTR-positive GEP-NETs who had progressed following prior...
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE achieved a 30.8% objective response rate and a 96% disease control rate with a manageable safety profile in patients with advanced SSTR-positive GEP-NETs who had progressed following prior...
In the phase 2 ALPHAMEDIX 02...
10/28/2025
Radiopharmaceutical Education Institute
News
12Pb-DOTAMTATE Yields Durable and Deep Responses in PRRT-Naïve GEP-NETs
10/28/2025
Janelle Bradley
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02...
10/28/2025
Radiopharmaceutical Education Institute

About

The NANETS Annual Symposium provides a dedicated space for medical and research professionals to exchange insights, explore innovative techniques, and collaborate on the future of NET diagnosis and treatment.

This three-day event is designed by medical professionals, for medical professionals, and remains the leading annual educational conference focused exclusively on NET disease.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use